B. Mark Evers
YOU?
Author Swipe
View article: Colon cancer in Appalachian Kentucky: Unique genetic, microbiome and obesity findings in a cohort comparison
Colon cancer in Appalachian Kentucky: Unique genetic, microbiome and obesity findings in a cohort comparison Open
We investigated colon cancer genomics and microenvironmental features in the Appalachian Kentucky population, a group with the highest incidence of colon cancer in the United States. We assessed two inter-related risk factors for colon can…
View article: Neurotensin inhibits AMPK activity and concurrently enhances FABP1 expression in small intestinal epithelial cells associated with obesity and aging
Neurotensin inhibits AMPK activity and concurrently enhances FABP1 expression in small intestinal epithelial cells associated with obesity and aging Open
We previously demonstrated that neurotensin, a 13-amino-acid gut hormone peptide, enhances small intestinal epithelial cell fatty acid uptake through inhibition of AMPK. Here, utilizing Drosophila and mouse models in vivo, as well as mouse…
View article: GDP-mannose 4,6-dehydratase is a key driver of MYCN-amplified neuroblastoma core fucosylation and tumorigenesis
GDP-mannose 4,6-dehydratase is a key driver of MYCN-amplified neuroblastoma core fucosylation and tumorigenesis Open
MYCN-amplification is a genetic hallmark of ~40% of high-risk neuroblastomas (NBs). Altered glycosylation is a common feature of adult cancer progression, but little is known about how genetic signatures such as MYCN-amplification alter gl…
View article: pH-responsive bond as a linker for the release of chemical drugs from RNA–drug complexes in endosome or lysosome
pH-responsive bond as a linker for the release of chemical drugs from RNA–drug complexes in endosome or lysosome Open
Emerging phenomena have signaled that RNA therapeutics will be the third milestone in pharmaceutical drug development. RNA nanoparticles display motile and deformable properties that lead to (1) fast and efficient tumor accumulation via bo…
View article: Upregulation of Fatty Acid Synthase Increases Activity of β-Catenin and Expression of NOTUM to Enhance Stem-like Properties of Colorectal Cancer Cells
Upregulation of Fatty Acid Synthase Increases Activity of β-Catenin and Expression of NOTUM to Enhance Stem-like Properties of Colorectal Cancer Cells Open
Dysregulated fatty acid metabolism is an attractive therapeutic target for colorectal cancer (CRC). We previously reported that fatty acid synthase (FASN), a key enzyme of de novo synthesis, promotes the initiation and progression of CRC. …
View article: miR‐27a‐3p regulates intestinal cell proliferation and differentiation through Wnt/β‐catenin signalling
miR‐27a‐3p regulates intestinal cell proliferation and differentiation through Wnt/β‐catenin signalling Open
Intestinal stem cells differentiate into absorptive enterocytes, characterised by increased brush border enzymes such as intestinal alkaline phosphatase (IAP), making up the majority (95%) of the terminally differentiated cells in the vill…
View article: Supplementary Figure 6 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplementary Figure 6 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
FBXO24 expression is associated with a good prognosis.
Table S1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
The used antibodies including company, catalog number and dilution.
Table S3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
Supplemental Table S3. Tumor samples used for analysis
View article: Table S2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Table S2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
The sequence of primers for RT-qPCR and ChIP-qPCR.
View article: Supplementary Figure 2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplementary Figure 2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
FBXO24 degrades LSD1.
View article: Table S4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Table S4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
Supplemental table 4. Tumor samples with Lymph node metastases of breast cancer.
View article: Table S1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Table S1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
The used antibodies including company, catalog number and dilution.
View article: Supplementary Figure 1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplementary Figure 1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
FBXO24 regulates LSD1 at protein levels.
View article: Supplementary Figure 5 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplementary Figure 5 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
Association between FBXO24 expression and tumor stage and overall survival (OS) in the TCGA dataset.
View article: Data from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Data from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
LSD1, a critical chromatin modulator, functions as an oncogene by demethylation of H3K4me1/2. The stability of LSD1 is governed by a complex and intricate process involving ubiquitination and deubiquitination. Several deubiquitinases prese…
Supplementary Figure 3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
FBXO24 blocks tumor migration and invasion.
Supplementary Figure 6 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
FBXO24 expression is associated with a good prognosis.
View article: Supplementary Figure 1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplementary Figure 1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
FBXO24 regulates LSD1 at protein levels.
View article: Supplementary Figure 5 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplementary Figure 5 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
Association between FBXO24 expression and tumor stage and overall survival (OS) in the TCGA dataset.
View article: Table S2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Table S2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
The sequence of primers for RT-qPCR and ChIP-qPCR.
View article: Supplemental Figure 4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental Figure 4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
The expression of FBXO24 is inversely associated with the expression of LSD1.
View article: Table S4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Table S4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
Supplemental table 4. Tumor samples with Lymph node metastases of breast cancer.
View article: Supplementary Figure 3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplementary Figure 3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
FBXO24 blocks tumor migration and invasion.
View article: Supplementary Figure 2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplementary Figure 2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
FBXO24 degrades LSD1.
Table S3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
Supplemental Table S3. Tumor samples used for analysis
View article: Supplemental Figure 4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental Figure 4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination Open
The expression of FBXO24 is inversely associated with the expression of LSD1.